Molina Juan de Dios, de Pablo Silvia, López-Muñoz Francisco, Alamo Cecilio, Blasco-Fontecilla Hilario, González-Parra Silvia
Acute Inpatients Unit, Doctor Rodríguez Lafora Psychiatric Hospital, Carretera de Colmenar Viejo, Km. 13.800, Madrid 28049, Spain.
Prog Neuropsychopharmacol Biol Psychiatry. 2006 Sep 30;30(7):1353-5. doi: 10.1016/j.pnpbp.2006.03.008. Epub 2006 Apr 24.
Amphetamine withdrawal can induce a condition with the symptoms of major depression. We report the case of a 46-year-old woman with antecedents of abuse of amphetamines and amphetamine derivatives from age 16 to age 41, who in the 5 years since withdrawal presented recurrent depression resistant to treatment. She was treated with maximum doses of selective serotonin reuptake inhibitors and lithium, but there was no remission of symptoms. On being treated with reboxetine, a selective noradrenaline reuptake inhibitor, euthymia was achieved, without negative after effects. Several studies have shown that noradrenaline plays an important role in the modulation of the response to amphetamines. The findings in this case suggest that reboxetine may constitute an interesting alternative for the treatment of amphetamine withdrawal syndrome (AWS).
苯丙胺戒断可诱发一种具有重度抑郁症状的病症。我们报告了一例46岁女性病例，该女性从16岁至41岁有滥用苯丙胺及苯丙胺衍生物的既往史，在戒断后的5年里出现了对治疗耐药的复发性抑郁症。她接受了最大剂量的选择性5-羟色胺再摄取抑制剂和锂盐治疗，但症状未缓解。在用选择性去甲肾上腺素再摄取抑制剂瑞波西汀治疗后，达到了情绪正常，且无不良后遗症。多项研究表明，去甲肾上腺素在调节对苯丙胺的反应中起重要作用。该病例的研究结果表明，瑞波西汀可能是治疗苯丙胺戒断综合征（AWS）的一种有趣的替代药物。
